Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
2.850
-0.100 (-3.39%)
At close: Oct 8, 2025, 4:00 PM EDT
2.850
0.00 (0.00%)
After-hours: Oct 8, 2025, 7:02 PM EDT

Akebia Therapeutics Stock Forecast

Stock Price Forecast

The 5 analysts that cover Akebia Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $6.90, which forecasts a 142.11% increase in the stock price over the next year. The lowest target is $6.00 and the highest is $8.00.

Price Target: $6.90 (+142.11%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$6.00$6.90$7.00$8.00
Change+110.53%+142.11%+145.61%+180.70%
* Price targets were last updated on Jun 4, 2025.

Analyst Ratings

The average analyst rating for Akebia Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingMay '25Jun '25Jul '25Aug '25Sep '25Oct '25
Strong Buy233333
Buy222222
Hold000000
Sell000000
Strong Sell000000
Total455555

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Initiates
$8
Strong BuyInitiates$8+180.70%Jun 4, 2025
Leerink Partners
Leerink Partners
Buy
Initiates
$7
BuyInitiates$7+145.61%Apr 28, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$7.5
Strong BuyReiterates$7.5+163.16%Apr 4, 2025
Jefferies
Jefferies
Strong Buy
Initiates
$6
Strong BuyInitiates$6+110.53%Apr 1, 2025
Piper Sandler
Piper Sandler
Buy
Maintains
$4$6
BuyMaintains$4$6+110.53%Mar 14, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
230.52M
from 160.18M
Increased by 43.91%
Revenue Next Year
304.49M
from 230.52M
Increased by 32.09%
EPS This Year
-0.02
from -0.33
EPS Next Year
0.10
from -0.02
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
294.64M211.65M292.48M194.62M160.18M230.52M304.49M
Revenue Growth
-12.05%-28.17%38.19%-33.46%-17.70%43.91%32.09%
EPS
-2.78-1.70-0.52-0.28-0.33-0.020.10
EPS Growth
-------
Forward PE
------27.94
No. Analysts
-----77
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20252026202720282029
High274.8M416.1M
Avg230.5M304.5M
Low200.1M223.3M

Revenue Growth

Revenue Growth20252026202720282029
High
71.6%
80.5%
Avg
43.9%
32.1%
Low
24.9%
-3.1%

EPS Forecast

EPS20252026202720282029
High0.180.43
Avg-0.020.10
Low-0.12-0.20

EPS Growth

EPS Growth20252026202720282029
High--
Avg--
Low--
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.